NCT01547806View on ClinicalTrials.gov

Collection of Transplant Stem Cells for Plasma Cell Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

February 22, 2012

Primary Completion Date

June 17, 2014

Study Completion Date

January 11, 2018

Conditions
Plasma Cell MyelomaMultiple Myeloma
Interventions
DRUG

Filgrastim

Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days

DRUG

Plerixafor

Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight

PROCEDURE

Apheresis

The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 106 CD34+ cells/kg.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01547806 - Collection of Transplant Stem Cells for Plasma Cell Myeloma | Biotech Hunter | Biotech Hunter